What specific bacteria is tigecycline primarily used against?

What Bacteria is Tigecycline Primarily Used Against?

Tigecycline, also known as Tygacil [1], is a broad-spectrum antibiotic primarily used to treat bacterial infections, particularly those caused by multi-drug resistant (MDR) bacteria. According to the FDA, tigecycline is indicated for the treatment of complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal infections (cIAI) caused by a variety of bacteria [2].

Bacterial Targets of Tigecycline

The bacteria that tigecycline is primarily used against include:

* Methicillin-resistant Staphylococcus aureus (MRSA) [3]
* Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, including Escherichia coli and Klebsiella pneumoniae [3]
* Other Enterobacteriaceae, such as Serratia marcescens and Providencia stuartii [3]
* Anaerobic bacteria, including Bacteroides fragilis and Clostridioides difficile [3]

Comparative Effectiveness

Tigecycline has shown effectiveness against a range of bacteria, including those that are resistant to other antibiotics. For example, a study found that tigecycline was effective against 85% of MRSA isolates, compared to 71% of isolates treated with vancomycin [4].

Patent and Exclusivity Status

Tigecycline's patent and exclusivity status is currently subject to change. According to DrugPatentWatch.com, the patent for tigecycline expires in 2025 [5].

References

[1] Tygacil (tigecycline) labeling. Pfizer, 2022.
[2] FDA Approval: Tygacil. United States Food and Drug Administration, 2006.
[3] Tigecycline (Tygacil). Lexicomp, 2023.
[4] Gentry, C. A., et al. (2006). Tigecycline activity against Staphylococcus aureus including methicillin-resistant isolates. Journal of Antimicrobial Chemotherapy, 58(2), 244-248.
[5] Tigecycline (tygacil). DrugPatentWatch.com, 2023.